Y
Yoav H. Messinger
Researcher at Children's Hospitals and Clinics of Minnesota
Publications - 91
Citations - 3782
Yoav H. Messinger is an academic researcher from Children's Hospitals and Clinics of Minnesota. The author has contributed to research in topics: Pleuropulmonary blastoma & DICER1 Syndrome. The author has an hindex of 27, co-authored 81 publications receiving 3086 citations.
Papers
More filters
Journal ArticleDOI
DICER1 Mutations in Familial Pleuropulmonary Blastoma
D. Ashley Hill,D. Ashley Hill,Jennifer Ivanovich,John R. Priest,Christina A. Gurnett,Louis P. Dehner,David M. Desruisseau,Jason A. Jarzembowski,Kathryn A. Wikenheiser-Brokamp,Brian K. Suarez,Alison J. Whelan,Gretchen M. Williams,Dawn Bracamontes,Dawn Bracamontes,Yoav H. Messinger,Paul J. Goodfellow +15 more
TL;DR: It is hypothesize that loss of DICER1 in the epithelium of the developing lung alters the regulation of diffusible factors that promote mesenchymal proliferation.
Journal ArticleDOI
DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies
Kris Ann P. Schultz,Gretchen M. Williams,Junne Kamihara,Douglas R. Stewart,Anne K. Harris,Andrew J. Bauer,Joyce Turner,Rachana Shah,Katherine A. Schneider,Kami Wolfe Schneider,Ann G. Carr,Laura A. Harney,Shari Baldinger,A. Lindsay Frazier,Daniel Orbach,Dominik T. Schneider,David Malkin,Louis P. Dehner,Yoav H. Messinger,D. Ashley Hill +19 more
TL;DR: Recommendations are provided for genetic testing; prenatal management; and surveillance for DICER1-associated pulmonary, renal, gynecologic, thyroid, ophthalmologic, otolaryngologic, and central nervous system tumors and gastrointestinal polyps.
Journal ArticleDOI
Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry.
Yoav H. Messinger,Douglas R. Stewart,John R. Priest,Gretchen M. Williams,Anne K. Harris,Kris Ann P. Schultz,Jiandong Yang,Leslie Doros,Philip S. Rosenberg,D. Ashley Hill,Louis P. Dehner +10 more
TL;DR: Pleuropulmonary blastoma (PPB) has 3 subtypes on a tumor progression pathway ranging from type I (cystic) to type II (Cystic/solid) and type III (completely solid).
Journal ArticleDOI
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger,Paul S. Gaynon,Paul S. Gaynon,Richard Sposto,Richard Sposto,Jeannette van der Giessen,Elena Eckroth,Jemily Malvar,Bruce Bostrom +8 more
TL;DR: The phase 2 expansion of this combination of bortezomib with chemotherapy is active in B-precursor ALL, and prophylactic antibiotics may be useful in reducing mortality.
Journal ArticleDOI
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
Yoav H. Messinger,Nancy J. Mendelsohn,William J. Rhead,David Dimmock,Eli Hershkovitz,Michael Champion,Simon Jones,Rebecca A. Olson,Amy L. White,Cara Wells,Deeksha Bali,Laura E. Case,Sarah P. Young,Amy S. Rosenberg,Priya S. Kishnani +14 more
TL;DR: The combination of rituximab with methotrexate ± intravenous gammaglobulins (IVIG) is an option for tolerance induction of CRIM-negative Pompe to ERT when instituted in the naïve setting or following antibody development.